Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection

Lantibiotics offer an untapped pipeline for the development of novel antibiotics to treat serious Gram-positive (+) infections including Clostridium difficile. Mutacin 1140 (MU1140) is a lantibiotic produced by Streptococcus mutans and acts via a novel mechanism of action, which may limit the develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kers, Johan A., Sharp, Robert E., Defusco, Anthony W., Park, Jae H., Xu, Jin, Pulse, Mark E., Weiss, William J., Handfield, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5864910/
https://www.ncbi.nlm.nih.gov/pubmed/29615987
http://dx.doi.org/10.3389/fmicb.2018.00415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5864910/
https://www.ncbi.nlm.nih.gov/pubmed/29615987
http://dx.doi.org/10.3389/fmicb.2018.00415

Ejemplares similares